Vaccine efficacy was 68.4 percent against RSV-associated acute respiratory disease; offers protection against subtypes A and B<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Dec. 14, 2023 (HealthDay News) — A single dose of mRNA-1345 vaccine is safe and results in lower incidence of respiratory syncytial virus (RSV)-associated disease in older patients, according to a study published in the Dec. 14 issue of the New England Journal of Medicine<\/em>.<\/p>\n Eleanor Wilson, M.D., from Moderna in Cambridge, Massachusetts, and colleagues conducted a randomized, phase 2 to 3 trial in which adults aged 60 years of age or older were randomly assigned to receive one dose of mRNA-1345 (50 \u00ce\u00bcg; 17,793 participants) or placebo (17,748 participants).<\/p>\n Participants were followed for a median of 112 days. The researchers found that vaccine efficacy was 83.7 and 82.4 percent against RSV-associated lower respiratory tract disease with at least two signs or symptoms and against the disease with at least three signs or symptoms, respectively. Vaccine efficacy against RSV-associated acute respiratory disease was 68.4 percent. Protection was seen against RSV subtypes A and B and was mainly consistent across subgroups defined according to age and coexisting conditions. Compared with those in the placebo group, participants in the mRNA-1345 group had a higher incidence of solicited local adverse reactions (58.7 versus 16.2 percent) and of systemic adverse reactions (47.7 versus 32.9 percent); most reactions were mild-to-moderate and transient. Overall, 2.8 percent of each trial group had serious adverse events.<\/p>\n “This phase 2 to 3 efficacy trial showed that a single 50-\u00ce\u00bcg dose of the mRNA-1345 vaccine in adults 60 years of age or older was efficacious against a spectrum of RSV-confirmed respiratory disease,” the authors write<\/p>\n The study was funded by Moderna, the manufacturer of the mRNA-1345 vaccine.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n